全文获取类型
收费全文 | 60612篇 |
免费 | 5394篇 |
国内免费 | 2518篇 |
专业分类
耳鼻咽喉 | 687篇 |
儿科学 | 1538篇 |
妇产科学 | 1138篇 |
基础医学 | 6184篇 |
口腔科学 | 1156篇 |
临床医学 | 5686篇 |
内科学 | 5533篇 |
皮肤病学 | 773篇 |
神经病学 | 2138篇 |
特种医学 | 3305篇 |
外国民族医学 | 52篇 |
外科学 | 7619篇 |
综合类 | 10451篇 |
现状与发展 | 19篇 |
预防医学 | 1633篇 |
眼科学 | 597篇 |
药学 | 4229篇 |
43篇 | |
中国医学 | 1875篇 |
肿瘤学 | 13868篇 |
出版年
2024年 | 119篇 |
2023年 | 860篇 |
2022年 | 1531篇 |
2021年 | 2627篇 |
2020年 | 2097篇 |
2019年 | 1896篇 |
2018年 | 1764篇 |
2017年 | 2011篇 |
2016年 | 2273篇 |
2015年 | 2442篇 |
2014年 | 3716篇 |
2013年 | 3776篇 |
2012年 | 3401篇 |
2011年 | 3765篇 |
2010年 | 3053篇 |
2009年 | 3085篇 |
2008年 | 3089篇 |
2007年 | 3347篇 |
2006年 | 3009篇 |
2005年 | 2675篇 |
2004年 | 2315篇 |
2003年 | 1952篇 |
2002年 | 1816篇 |
2001年 | 1626篇 |
2000年 | 1330篇 |
1999年 | 1213篇 |
1998年 | 1042篇 |
1997年 | 967篇 |
1996年 | 839篇 |
1995年 | 754篇 |
1994年 | 632篇 |
1993年 | 500篇 |
1992年 | 409篇 |
1991年 | 340篇 |
1990年 | 266篇 |
1989年 | 256篇 |
1988年 | 251篇 |
1987年 | 207篇 |
1986年 | 158篇 |
1985年 | 203篇 |
1984年 | 185篇 |
1983年 | 112篇 |
1982年 | 148篇 |
1981年 | 123篇 |
1980年 | 84篇 |
1979年 | 84篇 |
1978年 | 60篇 |
1977年 | 42篇 |
1976年 | 37篇 |
1975年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Kimberly A. Varker Edward W. Martin Dori Klemanski Bryan Palmer Manisha H. Shah Mark Bloomston 《Journal of gastrointestinal surgery》2007,11(12):1680-1685
Background
Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of
progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from
repeat TACE.
Methods
The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid
were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier
method.
Results
Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after
first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict
survival after repeat TACE.
Conclusion
Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is
safe and offers a viable treatment option.
Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007. 相似文献
102.
抑癌基因PTEN在胃癌中的表达及临床意义 总被引:1,自引:1,他引:0
目的探讨胃癌组织中PTEN基因表达与胃癌临床病理的关系及其对预后的判断价值。方法应用免疫组化SP技术和图像分析技术,研究PTEN在胃癌和正常胃黏膜组织中的表达情况及阳性表达面积、强阳性表达面积,分析与病理参数的关系,并采用Kaplan-Meier生存曲线分析不同表达水平对术后生存率的影响。结果发现胃癌组织PTEN表达阳性率、阳性面积、强阳性面积均明显低于正常胃黏膜组织(P〈0.01)。胃癌组织PTEN表达与胃癌组织分化程度、浸润深度、淋巴转移、肿瘤分期明显相关,术后3、5 a生存率低表达者明显低于高表达者(P均〈0.05)。结论PTEN基因表达低下或丢失与胃癌发生、浸润、转移有关,可作为预测术后生存率的指标。 相似文献
103.
目的 研究丙泊酚对大鼠肢体缺血再灌注损伤后肾组织中肿瘤坏死因子-α(tumornecrosisfactor-α,TNF-α)、核因子-κB(nuclear factor-κxB,NF-κB)表达的影响。方法 24只SD雄性大鼠,随机分为假手术对照组(A组),肢体缺血再灌注组(B组)和丙泊酚干预组(C组),每组8只。采用免疫组织化学方法检测TNF-α、NF-κB的表达,行图像分析半定量。结果 B组大鼠肾组织中TNF-α、NF-κB的表达明显高于A组(P〈0.05),C组明显低于B组(P〈0.05)。结论 肢体缺血再灌注后有明显肾损伤,丙泊酚对肢体缺血再灌注肾损伤有一定程度的保护作用,其机制可能与下调大鼠肢体缺血再灌注损伤肾组织中TNF-α、NF-κB的过度表达有关。 相似文献
104.
目的探讨经乙状窦后入路显微手术治疗桥小脑角占位性病变引起的继发性三叉神经痛的疗效。方法回顾分析我院2000年10月~2006年7月37例继发性三叉神经痛的临床资料,其中胆脂瘤18例,脑膜瘤8例,听神经瘤6例,三叉神经鞘瘤5例,均经乙状窦后入路显微手术切除肿瘤。结果肿瘤全切23例,次全切除10例,部分切除4例。35例疼痛症状消失(32例立即消失,3例术后2个月消失),随访3个月~5年无复发;2例无效。发生暂时性面瘫6例,面部麻木6例,无颅内感染及脑脊液漏。结论经乙状窦后入路显微手术是治疗继发性三叉神经痛安全有效的方法。 相似文献
105.
HLA-Cw研究进展 总被引:3,自引:0,他引:3
HLA—Cw属于经典的HLA—Ⅰ类基因,HLA—Cw分子与HLA—A、B分子一样具有高度多态性,广泛分布于有核细胞表面,不仅呈递内源性多肽给CD8^ T细胞,诱发特异性细胞杀伤效应,还可作为NK细胞免疫球蛋白样受体(KIR)的配体参与免疫反应。因此,HLA—Cw与疾病相关性研究、在移植免疫、抗病毒、抗肿瘤免疫中的作用日益受到重视。 相似文献
106.
107.
Ian F. Dunn Pankaj K. Agarwalla Alexander M. Papanastassiou William E. Butler Edward R. Smith 《Child's nervous system》2007,23(10):1191-1194
Objective Approximately 10% of patients with neurofibromatosis I (NFI) patients will have central nervous system (CNS) tumors. The most
common of these are hypothalamic–optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas. While isolated
pilocytic astrocytomas in NFI are well described, the appearance of multiple pilocytic astrocytomas in an individual patient
is less common. The most frequent combination in NFI patients with more than one pilocytic astrocytoma is optic tract/hypothalamic
and brainstem. Other combinations are exceedingly rare; multiple pilocytic astrocytomas have only been reported once in the
cerebral hemispheres in a patient with NFI. This report presents the first documented case, to our knowledge, of multiple
pilocytic astrocytomas in the cerebellum of a patient with NF1.
Methods Case report.
Conclusion The finding of multiple cerebellar pilocytic astrocytomas in a patient with NF1 is important because it expands the spectrum
of presentations for patients with NF1 and also highlights specific diagnostic and therapeutic challenges faced by the treating
physicians. The genetic and molecular basis of NF1 is reviewed. Strategies of diagnosis and treatment outlined here are relevant
to both patients with NF1 and all patients with multiple posterior fossa tumors. 相似文献
108.
Rho-Associated Kinase Inhibitor Reduces Tumor Recurrence After Liver Transplantation in a Rat Hepatoma Model 总被引:3,自引:0,他引:3
T. Ogawa H. Tashiro Y. Miyata Y. Ushitora Y. Fudaba T. Kobayashi K. Arihiro M. Okajima T. Asahara 《American journal of transplantation》2007,7(2):347-355
Tumor recurrence after liver transplantation still remains a significant problem in patients with hepatocellular carcinoma. The small GTPase Rho/Rho-associated kinase (ROCK) pathway is involved in the motility and invasiveness of cancer cells. We investigated whether tacrolimus activated the Rho/ROCK signal pathway to promote the invasiveness of rat hepatocellular carcinoma cells. We also investigated whether the ROCK inhibitor Y-27632 suppressed tumor recurrence after experimental liver transplantation in a rat hepatocellular carcinoma model. Orthotopic liver transplantation was performed in hepatocellular carcinoma cell line McA-RH7777-bearing rats. Tacrolimus was administered to liver transplant rats and these rats were divided into two groups: the Y-27632-treated (10 mg/kg, for 28 days) group and the Y-27632-untreated group. Tacrolimus enhanced the cancer cell migration and stimulated phosphorylation of the myosin light chain (MLC), a downstream effector of Rho/ROCK signaling. Y-27632 suppressed the cancer cell migration and tacrolimus-induced MLC phosphorylation. Suppression of tumor recurrence after liver transplantation and significant prolongation of survival were observed in the Y-27632-treated rats in comparison with theY-27632-untreated rats. Tacrolimus stimulates the Rho/ROCK signal pathway to enhance the invasiveness of hepatocellular carcinoma, and the ROCK inhibitor Y-27632 can be used as a new antimetastatic agent for the prevention of tumor recurrence after liver transplantation. 相似文献
109.
110.
目的 评价子宫动脉栓塞术治疗子宫肌瘤的近期疗效。方法 89例子宫肌瘤患者,采用Seldinger技术分别作左右子宫动脉主干插管检查和栓塞治疗,栓塞剂采用聚乙稀醇颗粒(PVA)或白芨混合颗粒。结果 72例(80.9%)完成随访,随访时间1~28个月。有94.1%(64/68)的患者月经复常;治疗后瘤体缩小25.2%~76.8%(M=41.3%)。除了术中术后疼痛(65例)和发热(16例)外,有2例因肌瘤坏死行子宫切除术,1例出现卵巢早衰。结论 子宫动脉栓塞术治疗子宫肌瘤的近期疗效满意,远期疗效尚待进一步观察。 相似文献